Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark
- 95.8% objective tumor response rate supports six-hour PEDMARK administration without apparent cisplatin antitumor interference
- No Grade 3 or Grade 4 hearing loss and no serious adverse event attributed to PEDMARK strengthen the Japan registration case
- Fennec is pursuing Japanese registration while seeking regional partnering or licensing opportunities
- Japan expansion remains a catalyst, but approval and commercial uptake remain subject to regulatory review and additional execution risks
Other items in this filing:
- Item 8.01: Other Events
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.